Summary:
Aurobindo Pharma reported a 32.7% year-on-year increase in Q2 FY27 net profit attributable to shareholders to ₹1,126 crore, while revenue grew 23.9% to ₹10,263 crore. Strong US and European sales, higher EBITDA and product launches supported performance.
Aurobindo Pharma (NSE: AUROPHARMA) reported a 32.7% YoY increase in net profit attributable to shareholders in Q2FY27, driven by higher revenue from the United States and European markets. Revenue rose 23.9% to ₹10,263 crore, the company’s best quarterly sales performance.
Aurobindo Pharma Q2FY27 Result
The drug maker said net profit attributable to owners stood at ₹1,126 crore as against around ₹848 crore in Q2FY26.
Total consolidated profit after tax including non-controlling interests was ₹ 1,124 crore, up 32.5%. The difference is in the treatment of minority interests.
Revenue from operations increased to ₹10,263 crore as compared to ₹8,286 crore during the same quarter last year.
EBITDA grew 28.5% YoY to ₹2,156 crore from ₹1,678 crore.
EBITDA margin improved to 21% from 20.3%, up approximately 75 basis points.
The sequential performance was also positive with revenue up 12.2% to ₹9,150 crore in Q1FY27.
Total consolidated profit increased ~8.9% QoQ.
The company has also declared an interim dividend of ₹7 per share and the record date has been fixed for November 11, 2026.
Revenue Growth Powered by US and European Markets
The major chunk of Aurobindo Pharma’s revenue is derived from overseas pharmaceutical markets.
Its US business reported sales of ₹4,555 crore during Q2FY27, up 25.2% YoY.
The region represented approximately 44% of consolidated revenues.
European revenue grew 27.5% to ₹3,161 crore from ₹2,480 crore in the year ago.
Growth markets contributed ₹1,026 crore, up 16.3% YoY.
The active pharmaceutical ingredients business also performed well with revenue rising 20.9% to ₹1,162 crore.
The total revenue from formulations stood at ₹9,102 crore, up by 24.2%.
This geographic and business diversification has contributed to the company reporting record quarterly sales.
The performance was helped by growth in underlying businesses, new product introductions and the integration of acquired businesses.
Financial Reports
Regulation Product Launches and Approvals in the US
Aurobindo has a large generic pharma business in the US, which is an important market.
In Q2FY27, the company launched 10 products in the US including gAdvair and ADQUEY.
It got final US Food and Drug Administration approvals for 12 products.
The company cumulatively had 900 abbreviated new drug applications filed as of September 30, 2026, of which 747 were final approvals and 35 were tentative approvals.
The research and development expenditure was at ₹376 crore in the quarter against ₹344 crore in Q1FY27.
Aurobindo said its net cash, including investments, was about $189 mn at the end of September.
Investment in product development and manufacturing capabilities remains critical to underpinning international growth.
Why Aurobindo Pharma Shares Surged?
Aurobindo Pharma shares climbed about 2.1% to ₹1,740.10 in early trading on November 5 after the company announced its quarterly results.
The positive move came after the company reported record revenue, higher margins and strong growth across its major international markets.
But the pharmaceutical business is still subject to regulatory risks, particularly around manufacturing inspections and approvals in the U.S.
Future profitability may also be affected by price pressure on generic medicines, foreign exchange movements and competition.
Q2FY27 performance reflects that Aurobindo’s growing global business is delivering revenue growth and higher earnings.
The success in maintaining this performance will depend on the success of its product launches, regulatory compliance and further improvements in its product mix.
